The Filing Desk

Monte Rosa Therapeutics vs ImmunityBio

Monte Rosa Therapeutics GLUE · ImmunityBio IBRX · Biotechnology

Monte Rosa Therapeutics reported revenue of $124 million in fiscal 2025, about the same as ImmunityBio's $113 million in fiscal 2025. Monte Rosa Therapeutics' revenue grew 63.5% in its latest year, and ImmunityBio's grew 668.3%. Monte Rosa Therapeutics had an operating margin of -43.8%, against -226.0% at ImmunityBio. Free cash flow was −$28 million at Monte Rosa Therapeutics and −$309 million at ImmunityBio.

Side by side

Monte Rosa TherapeuticsImmunityBio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$124M$113M
Revenue growth63.5%668.3%
Revenue growth a year, last 5 years—185.2%
Gross margin—99.3%
Operating margin−43.8%−226.0%
Net margin−31.2%−310.2%
Free cash flow−$28M−$309M
Free cash flow margin−22.2%−272.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.4%31.3%
Last close$9.37$6.02
P/E at the last close——
Insider trades, last 12 months—sold $8.4 million
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Monte Rosa TherapeuticsImmunityBio
Operating margin
Percent of revenue
Monte Rosa TherapeuticsImmunityBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Monte Rosa TherapeuticsImmunityBio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Monte Rosa Therapeutics and ImmunityBio pages.